KB707 + Opdualag + KEYTRUDA ®( Pembrolizumab)
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cancer
Conditions
Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
Trial Timeline
Oct 31, 2023 → Jul 1, 2027
NCT ID
NCT05970497About KB707 + Opdualag + KEYTRUDA ®( Pembrolizumab)
KB707 + Opdualag + KEYTRUDA ®( Pembrolizumab) is a phase 1/2 stage product being developed by Krystal Biotech for Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05970497. Target conditions include Cancer, Melanoma Stage III, Melanoma Stage IV.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05970497 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E7389 | Eisai | Phase 1 | 33 |
| Veliparib | AbbVie | Phase 2 | 52 |
| AK-105 | Akeso | Phase 1 | 32 |
| XL820 | Exelixis | Phase 1 | 30 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 69 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 69 |
| ALT-P7 (HM2-MMAE) | Alteogen | Phase 1 | 33 |
| pegylated liposomal doxorubicin (PLD) + PD-1 | CSPC Pharmaceutical Group Limited | Phase 2 | 51 |
| Biomarkers blood, urine and microbiota samples | Eli Lilly | Pre-clinical | 23 |
| gemcitabine + paclitaxel + bevacizumab | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| LY3300054 + Prexasertib | Eli Lilly | Phase 1 | 33 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 30 |
| Cetuximab + Oxaliplatin + Capecitabine | Eli Lilly | Phase 2 | 52 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + Adriamycine + Paclitaxel | Eli Lilly | Phase 2 | 52 |
| Selpercatinib | Eli Lilly | Pre-clinical | 23 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 77 |
| NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRT | Nanobiotix | Phase 1/2 | 36 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |